Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

Conshohocken, Pa. Friday, August 1, 2025, 15:00 Hrs [IST] ...

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license ...

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was ...

Madrigal Pharmaceuticals Inc. and CSPC Pharmaceutical Group Ltd. have entered into an exclusive global license agreement for CSPC’s SYH-2086, a preclinical oral small-molecule glucagon-like peptide-1 ...

The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.